Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO5466731 + RO5190591 + ritonavir + ribavirin + RO5024048
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination experimental antiviral regimen comprising four investigational direct-acting antivirals—RO5466731, RO5190591, RO5024048—and two approved agents, ritonavir and ribavirin, studied primarily for the treatment of chronic hepatitis C (HCV) genotype 1. Each component targets different stages in the HCV life cycle or host-virus interaction, aiming for synergistic viral suppression and improved response in treatment-naïve and interferon null-responder patients. RO5466731, RO5190591, and RO5024048 are Roche investigational DAAs for HCV, while ritonavir acts as a pharmacokinetic enhancer (‘booster’), and ribavirin is a nucleoside analog with broad-spectrum antiviral activity. The development and trials of this combination were led by Hoffmann-La Roche[1][3][5].
- Other names
- RO5466731 + RO5190591 + ritonavir + ribavirin + RO5024048
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)CYP3A4 (Cytochrome P450 3A4)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on RO5466731 + RO5190591 + ritonavir + ribavirin + RO5024048.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO5466731 + RO5190591 + ritonavir + ribavirin + RO5024048.